A successful DRUG-seq handoff starts before anyone touches a plate. The fastest way to get decision‑ready results is to align on one primary decision, deliver a clean plate map and minimal metadata, pre‑declare your controls and comparisons, and agree on a digestible deliverables package with clear review gates. This DRUG-seq kickoff checklist is designed so a vendor can run and report with minimal rework—and you can defend decisions with auditable inputs.

Key Takeaways

• One clear decision (rank, compare, or explain) drives experimental design, contrasts, and final reporting.
• A complete, machine‑readable plate map and a short condition dictionary prevent mislabeling and enable reproducible analysis.
• Minimal, standardized metadata makes results interpretable and protects against hidden confounders.
• Controls and replicate logic buy more interpretability than extra depth alone; distribute controls across every plate.
• Pre‑agreed deliverables, file/folder names, and a README with versions turn raw data into decision‑ready output.
• Lightweight review gates—intake, run QC snapshot, and draft results review—catch problems early and keep timelines predictable.

Use This DRUG-seq Kickoff Checklist

A kickoff checklist aligns goals, inputs, and review gates so your partner can run and report with minimal rework.

Who It Helps (R&D, PM, Bioinformatics, Outsourcing)

• Outsourcing/vendor managers: use this as a standard intake packet and SOW appendix.
• R&D PMs/PIs: set success criteria, contrasts, and review gates upfront.
• Bioinformatics leads: lock down deliverables, versions, and reproducibility expectations.
• Bench scientists: confirm plate layout, naming rules, units, and handling notes.

What "Ready to Start" Means

• You have picked one primary decision and written success criteria.
• The plate map is complete and machine‑readable, including controls and randomization notes.
• Minimal metadata is filled and consistent on units and naming.
• Controls and replicate logic are declared, with explicit "do not compare" rules.
• Deliverables and folder/file conventions are agreed; review gates and triggers are noted.

How to Use It in 15 Minutes

1. PM + Outsourcing lead: confirm the decision and success criteria (3 minutes).

2. Bench scientist: paste the plate map dictionary template and fill wells, doses, times, controls (5 minutes).

3. R&D scientist: fill minimal metadata and confounder flags (4 minutes).

4. Bioinformatics lead: approve deliverables manifest, folder names, and review gates (3 minutes).

Define the Decision

One primary decision (rank, compare, or explain) drives design choices and what the final report must show.

Pick One Primary Decision

Decide which of the following is primary:

• Rank: prioritize compounds/conditions by transcriptional impact or signature match.
• Compare: quantify differences between predefined conditions (e.g., dose‑response, A vs B).
• Explain: interpret mechanism‑of‑action through signatures or pathways.

Your choice informs contrasts, control selection, and report views. For an example of structured combination screening readouts, see the 2022 Nature Communications Combi-seq article (open access).

Write Success Criteria Without Overpromising

State observable outputs, not numeric thresholds. Example:

• "Provide a ranked list with top genes and per‑contrast effect sizes, plus QC summaries and an auditable README with version pinning."
• "Demonstrate stability of rankings under reasonable model variations."

Avoid promises on universal read depth or fixed replicate counts; these are context‑dependent and should be agreed qualitatively.

Pre‑Declare Must‑Have Comparisons

List the intended contrasts, e.g., "compound_X vs vehicle at 24 h," "dose_high vs dose_low," "A vs B at matched time and plate." Document out‑of‑scope comparisons now to prevent invalid cross‑plate requests later.

For reproducible reporting structures and design matrices, align with principles from MINSEQE and GEO's validation categories that emphasize experimental factors and replicate structure; the Functional Genomics Data Society explains these expectations in the MINSEQE guideline and NCBI details validation checks in GEO documentation.

Share the Plate Map

A complete plate map and condition dictionary prevent labeling errors and support reproducible analysis.

Layout Essentials (Wells, Dose, Time, Replicates)

Distribute conditions and controls across the entire plate to average positional biases. Where practical, randomize within blocks and scatter controls on every plate. Mitigate edge effects by distribution rather than clustering; if your assay is sensitive, consider using buffer in extreme edge wells and note it in the dictionary, as discussed in high‑throughput screening best practices and edge‑effect reviews.

Copy‑paste plate map dictionary schema (CSV):

well,sample_id,compound_id,dose_value,dose_unit,time_value,time_unit,replicate_id,randomization_block,control_type
A01,SID001,CMP_A,0.1,uM,24,h,1,B1,vehicle
A02,SID002,CMP_A,0.3,uM,24,h,2,B2,
A03,SID003,CMP_A,1.0,uM,24,h,3,B3,
...
H11,SID190,CMP_REF,1.0,uM,24,h,1,B4,positive
H12,SID191,BASELINE,0,NA,0,h,1,B4,baseline

Notes:

• control_type values: vehicle, baseline, positive, toxicity_flag (if applicable).
• randomization_block is optional but recommended for modeling positional effects.
• sample_id is unique per well.

Naming Rules and Units

• Use consistent, machine‑readable names: lowercase_with_underscores; avoid spaces and special characters.
• Dose and time must have separate value and unit fields (dose_value/dose_unit; time_value/time_unit) to prevent unit mismatches.
• Compound IDs should be stable across projects; keep a lookup table in /00_intake/.

Randomization Notes and Constraints

• Document constraints (e.g., biosafety cabinet location, liquid‑handling limits) and any banned well positions.
• State whether outer wells are filled with buffer/media and excluded from analysis.

Authoritative context on layout and edge effects can be found in the Assay Guidance Manual's image‑based high‑content screening guidelines and open reviews on plate edge effects that discuss evaporation and temperature gradients in multiwell assays; see the National Center for Advancing Translational Sciences' Assay Guidance Manual and open reviews on edge effects in high‑throughput assays for practical mitigation strategies.

Send Key Metadata

Minimal metadata makes results interpretable and prevents false conclusions from hidden confounders.

Capture a compact, standards‑aligned spreadsheet plus a README. The fields below reflect MINSEQE categories and GEO/ENCODE organization of metadata for bulk RNA‑seq.

Model Metadata (Cell Line, Passage, Conditions)

• model_id, model_type (e.g., cell_line, primary_cells), passage
• seeding_density (cells_per_well), media

Treatment Metadata (IDs, Solvent, Handling)

• compound_id, dose_value, dose_unit
• vehicle (e.g., DMSO), vehicle_pct
• handling_notes (e.g., mixing, incubation specifics)

Process Metadata (Batch, Timing Notes)

• batch_id, run_date, operator_initials
• treatment_start_time, harvest_time
• reference_genome, annotation_release (for version pinning in README)

Confounders to Flag (Growth, Stress, Toxicity)

• notes_confounds (e.g., slow growth, visible stress, contamination concerns)

Copy‑paste minimal metadata template (TSV):

sample_id	model_id	model_type	passage	seeding_density	media	compound_id	dose_value	dose_unit	vehicle	vehicle_pct	handling_notes	treatment_start_time	harvest_time	batch_id	run_date	operator_initials	notes_confounds
SID001	CL_A	cell_line	P6	10000	DMEM+10%FBS	CMP_A	0.1	uM	DMSO	0.1	gentle_mix_10s	2026-02-13T10:00	2026-02-14T10:00	B001	2026-02-15	AB	-
SID002	CL_A	cell_line	P6	10000	DMEM+10%FBS	CMP_A	0.3	uM	DMSO	0.1	gentle_mix_10s	2026-02-13T10:00	2026-02-14T10:00	B001	2026-02-15	AB	-
SID191	CL_A	cell_line	P6	10000	DMEM+10%FBS	BASELINE	0	NA	NA	NA	-	2026-02-13T00:00	2026-02-13T00:00	B001	2026-02-15	AB	baseline_time_zero

Why this matters: The Functional Genomics Data Society's MINSEQE guideline and NCBI's GEO validation pages emphasize complete sample annotations, experimental factors, and protocol summaries so analyses are auditable and reusable.

Align Controls and Replicates

Controls and replicate logic determine whether rankings are credible or distorted by plate effects and generic responses.

Baseline and Vehicle Controls

• Include baseline/time‑zero if applicable and vehicle controls on every plate; scatter them across the grid. Vehicle controls establish the noise floor and normalization anchors.

Reference/Positive Controls (If Available)

• Use well‑characterized reference compounds sparingly but consistently to validate assay sensitivity and to sanity‑check signature directionality.

Replicate Logic and Practical Randomization

• Favor biological replicates aligned to your decision power and budget. State replicate intent qualitatively (e.g., "biological replicates recommended; final count determined by decision power and resources").
• Randomize within blocks where feasible; record randomization_block in the plate dictionary for modeling.

"Do Not Compare" Rules

• Prohibit cross‑plate or cross‑batch contrasts unless designed with bridging controls and an agreed normalization plan.
• Disallow comparisons with mixed units, mismatched timepoints, or inconsistent vehicle percentages.

Copy‑paste control matrix (CSV):

control_type,mitigated_risk,placement_notes,do_not_compare_rules
vehicle,drift|plate_effects,scatter_every_plate_checkerboard,do_not_compare_across_batches_without_bridging_controls
baseline,time_zero|non_specific_response,include_if_applicable_scattered,do_not_compare_with_mismatched_timepoints
positive,assay_window|sensitivity,place_sparingly_across_plate,do_not_use_as_experimental_control_for_primary_contrasts
toxicity_flag,non_specific_stress,log_and_scatter_as_reference,do_not_rank_as_hit;use_for_filtering_context

For foundations on control design and HTS assay validation, consult the National Center for Advancing Translational Sciences' Assay Guidance Manual. For RNA‑seq study design philosophy on replicates and power, see an open practical guide to reproducible gene expression analysis in the scientific literature that discusses replicate strategy and power without prescribing universal numbers.

Confirm Deliverables

Deliverables should be agreed up front so results arrive in a decision‑ready structure your team can use immediately.

Minimum Package (QC, Matrices, Contrasts, Report)

Request, at minimum:

• Run‑level QC summary (FastQC aggregated into MultiQC) for a quick stability check before heavy processing. FastQC and MultiQC are widely used for read‑level and consolidated QC snapshots in NGS.
• Gene‑level matrices (counts and a normalized matrix such as TPM/FPKM) suitable for differential analysis.
• Design/contrast definitions used in analysis (tabular or YAML + R object) matching the declared decision.
• A succinct HTML/PDF report summarizing QC, top contrasts, and ranked results with clear headings.
• A README capturing pipeline and reference versions and a brief methods synopsis (aligner, quantifier, reference genome build, annotation release).

If you outsource DRUG‑seq (RUO), align deliverables and acceptance criteria up front with a neutral, written scope; for example, the CD Genomics DRUG‑seq service page provides a concise overview suitable for research‑use‑only context and can help frame discussions on inputs and outputs. See the DRUG‑seq service description under biomedical NGS: CD Genomics — DRUG‑seq service.

Optional Outputs (Signatures, Pathways, Hypotheses)

• Signature exports (e.g., ranked gene lists per contrast) and compact pathway summaries to support "explain" decisions.
• Optional R‑compatible objects (e.g., SummarizedExperiment‑like) to accelerate downstream analysis.

File and Folder Conventions

Adopt a predictable tree with version pinning in README:

project_slug/
 00_intake/
 plate_map.csv
 metadata.tsv
 design_matrix.tsv
 contrasts.tsv
 README_intake.md
 01_run_qc/
 fastqc/ # raw per-sample FastQC outputs
 multiqc_report.html
 02_counts_matrices/
 gene_counts.tsv
 gene_tpm.tsv
 03_contrasts/
 design_matrix.tsv
 contrasts.tsv
 design.Rds # or design.yaml
 04_reports/
 summary.html
 figures/
 99_archive/
 bam/
 logs/
 bigwig/
 README.md # pipeline version, reference genome, annotation release, software hashes

README.md template (append to project root):

# Project README (Reproducibility Summary)
- Pipeline/version: <name> <vX.Y.Z>
- Aligner/quantifier: <tool> <vX.Y.Z>
- Reference genome: <GRCh38 or mm10>, build <release>
- Annotation release: <Ensembl vXX or GENCODE vXX>
- Key parameters: <brief>
- Design/contrasts files: paths
- Notes: any deviations from the SOW or intake packet

Context and examples of typical outputs: see the consolidated output documentation from community pipelines such as nf‑core/rnaseq, which detail matrices, logs, and report artifacts; read‑level QC tools provide the run‑level snapshot that supports Gate 2 below; and the ENCODE Uniform Analysis Pipelines overview illustrates common QC summaries (mapping stats, replicate agreement) that many labs mirror in bulk RNA‑seq reporting.

Also review a concise DRUG‑seq workflow principles primer for stage‑by‑stage expectations across library preparation, sequencing, and analysis handoffs: DRUG‑seq workflow principles and applications.

Set Review Gates

Simple review gates catch problems early by checking inputs, run QC, and result stability in stages.

Gate 1: Intake Check

• Are the plate map and metadata complete, with consistent units and naming? Are controls present on every plate and scattered?
• Do the declared contrasts answer the chosen decision (rank/compare/explain)?
• Are deliverables and folder/file names agreed? Is the README version template in place?

Reference patterns for metadata completeness come from the Functional Genomics Data Society's MINSEQE guidance and NCBI's GEO validation categories for high‑throughput sequencing submissions.

Gate 2: Run QC Snapshot

• Review FastQC/MultiQC to identify major quality issues (adapter content, duplication, GC distribution outliers) before full processing.
• Confirm control wells behave plausibly (no obvious labeling errors). If needed, perform light trimming or re‑runs before proceeding.

See the maintainers' documentation for FastQC and the project page for MultiQC for what these snapshots typically report.

Gate 3: Draft Results Review

• Do the rankings/contrasts answer the primary decision? Are outcomes stable under reasonable model variations?
• Are replicate agreements and control behaviors consistent with expectations? If not, consider corrective action.

For examples of post‑processing QC summaries and replicate‑agreement views, see the ENCODE Uniform Analysis Pipelines overview (2020).

Rerun vs Redesign Triggers

• Mislabeling, unit mismatches, missing or mis‑distributed controls, or results that cannot address the primary decision.
• Severe plate effects without mitigation; unresolved batch effects; contradiction between metadata and plate dictionary.

Normalization and cross‑plate cautions are discussed in open analyses of HTS normalization frameworks; these reinforce the value of planning bridging controls and explicit modeling before making cross‑plate claims.

Avoid Common Mistakes

Most delays come from missing plate maps, ambiguous naming, and undefined comparisons—not sequencing itself.

Label/Unit Mismatches

• Separate value and unit fields for dose and time. Keep vehicle percentage explicit. Lock naming conventions before kickoff.

Unclear Primary Decision

• If you don't choose rank vs compare vs explain, you'll invite scope creep and ambiguous reporting.

Cross‑Plate Comparisons Without a Plan

• Prohibit until bridging controls and a normalization plan are agreed. Otherwise, you risk invalid contrasts and rework.

Controls Added Too Late

• Controls are not an afterthought—scatter them on every plate to enable normalization and drift detection.

(Optional visual) A compact "Mistake → Symptom → Fix" flowchart can reinforce these points in internal training decks.

FAQ

What Is the Minimum Information Needed to Start?

• The filled plate map dictionary, minimal metadata TSV, declared primary decision, contrasts list, and the deliverables manifest with folder/file conventions.

How Should I Name Conditions and Units to Avoid Confusion?

• Use lowercase_with_underscores; split dose/time into value and unit fields. Keep vehicle and vehicle_pct explicit.

What Controls Are "Must-Have" vs Optional?

• Vehicle and baseline/time‑zero (if pertinent) on every plate; disperse them. Reference/positive controls are recommended where available; toxicity flags help interpret non‑specific stress.

How Do I Decide Replicates Without Over-Designing?

• Favor biological replicates consistent with decision power and budget. Phrase as intent, not a fixed count; confirm with your analysis partner.

Can I Compare Across Plates or Batches?

• Only if you planned bridging controls and agreed on a normalization approach during kickoff. Otherwise, treat cross‑plate comparisons as out‑of‑scope.

What Deliverables Should I Request for Decision-Making?

• Run‑level QC (FastQC/MultiQC), count and normalized matrices, design/contrast files, an HTML/PDF report, and a README with pinned versions. Optionally request signature exports and R‑compatible objects for faster iteration.

Copy‑Paste Summary Templates (All in One Place)

Plate map dictionary (CSV):

well,sample_id,compound_id,dose_value,dose_unit,time_value,time_unit,replicate_id,randomization_block,control_type
<e.g., A01>,<SID001>,<CMP_A>,<0.1>,<uM>,<24>,<h>,<1>,<B1>,<vehicle|baseline|positive|toxicity_flag|>

Minimal metadata (TSV):

sample_id	model_id	model_type	passage	seeding_density	media	compound_id	dose_value	dose_unit	vehicle	vehicle_pct	handling_notes	treatment_start_time	harvest_time	batch_id	run_date	operator_initials	notes_confounds

Control matrix (CSV):

control_type,mitigated_risk,placement_notes,do_not_compare_rules

Deliverables manifest and folder tree (text + README template):

project_slug/
 00_intake/ {plate_map.csv, metadata.tsv, design_matrix.tsv, contrasts.tsv}
 01_run_qc/ {fastqc/, multiqc_report.html}
 02_counts_matrices/ {gene_counts.tsv, gene_tpm.tsv}
 03_contrasts/ {design_matrix.tsv, contrasts.tsv, design.Rds|design.yaml}
 04_reports/ {summary.html, figures/}
 99_archive/ {bam/, logs/, bigwig/}
 README.md {pipeline, genome, annotation versions}

---

Choose Follow-Ups

• If your DRUG‑seq findings raise nuanced mechanistic questions or require richer isoform/novel gene context, consider a deeper transcriptome study for selected conditions. See an overview of approaches and deliverables here: Transcriptome sequencing — biomedical NGS.
• For teams new to DRUG‑seq, a concise workflow primer helps align expectations on stages, inputs, and outputs before kickoff. Read: DRUG‑seq workflow principles and applications.
• For broader study‑design references and operational templates, browse the organization's resource hub: Learning center — biomedical NGS.

---